tradingkey.logo
tradingkey.logo
Search

Arrowhead climbs on licensing agreement with Novartis for upto $2 billion

ReutersSep 2, 2025 5:01 PM
facebooktwitterlinkedin

Shares of Arrowhead Pharmaceuticals ARWR.O rise 11.8% to $24.63

Co says it will receive up to $2 billion from Novartis NOVN.S for an exclusive worldwide license to its experimental therapy ARO-SNCA that targets neuromuscular conditions such as Parkinson's disease

Arrowhead will receive $200 million and up to $2 billion in milestone payments and royalties on future sales of the therapy

Including session's move, stock was up 29.3% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI